HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- Venous thromboembolism guidelines aim to clarify proper care in areas with ‘a lot of uncertainty’
-
- Will heparin eventually be phased out with expanded use of DOACs for VTE?
- Difficult decisions: Slow changes for overuse of therapy at end of life John Sweetenham, MD, FRCP, FACP
- Recent advances in pancreatic cancer: From screening protocols to precision medicine paradigms Aatur D. Singhi, MD, PhD; Anirban Maitra, MBBS
- Experts applaud $500 million proposal for pediatric cancer research, but say more needed
- Self-care ‘critically important’ to avoid compassion fatigue, prevent burnout
- Third-line chemotherapy for NSCLC confers clinically meaningful PFS to immunotherapy-exposed patients
- Biosimilars to pave the way for cheaper cancer treatment in the US
- Autologous cell vaccine prolongs survival in newly diagnosed glioblastoma
-
- Entinostat plus pembrolizumab shows efficacy in anti-PD-1-resistant melanoma
- Rising PSA contributes to lack of clarity in nonmetastatic prostate cancer
- Future ‘very bright’ in acute myeloid leukemia
- FDA issues safety communication about use of robotically assisted devices for cancer surgeries
- FDA grants priority review to Revlimid as part of regimen for follicular, marginal zone lymphomas
- FDA grants priority review to fedratinib for myelofibrosis